Sweat Sensor Alerts Doctors And Patients To Impending Cytokine Storm In Real Time

Scientists have developed a sweat sensor that acts as an early warning system for a looming cytokine storm — a surge of pro-inflammatory immune proteins –, which could help doctors more effectively treat patients Covid-19. Doctors have previously recognized that patients who developed a "cytokine storm" were often the sickest and at the highest risk of dying. But a cytokine storm can also occur in other illnesses, such as influenza.

"Especially now in the context of Covid-19, if you could monitor pro-inflammatory cytokines and see them trending upwards, you could treat patients early, even before they develop symptoms," said Shalini Prasad, the project's principal investigator at the University of Texas at Dallas, US.

Researchers developed an extremely sensitive method to measure cytokine levels in tiny amounts of passive sweat. For the new sensor called the SWEATSENSER Dx, the team made sensor strips with antibodies against seven pro-inflammatory proteins: interleukin-6 (IL-6), IL-8, tumor necrosis factor-I (TNF-I), TNF-related apoptosis-inducing ligand, IL-10, interferon-I-induced protein-10, and C-reactive protein.

They inserted the strips into their device and, in a small observational study, they tested them on six healthy people and five people with influenza. Two of the sick people showed elevated cytokine levels, and in all participants, cytokines in passive sweat correlated with levels of the same proteins in serum.

ALSO READ: Here's Why Some Covid-19 Survivors Are At Risk Of Blood Clot

The SWEATSENSER Dx was sensitive enough to measure cytokines even in patients taking anti-inflammatory drugs, who excrete cytokines in the low-picogramme-per-milliliter concentration range. The device tracked cytokine levels for up to 168 hours before the sensor strip needed to be replaced, the researchers said. The team now plans clinical trials of the cytokine sensor in people with respiratory infections.

"Access to Covid-19 patients has been a challenge because healthcare workers are overwhelmed and don't have time to test investigational devices," Prasad says. "But we're going to continue to test it for all respiratory infections because the disease trigger itself doesn't matter — it's what's happening with the cytokines that we're interested in monitoring," she added. The results were presented at the spring meeting of the American Chemical Society being held online April 5-30. (IANS/JC)